Completed Clinical Trials

Pazopanib in Treating Patients With Malignant Pleural Mesothelioma

By April 24, 2017 No Comments


Advanced Malignant Mesothelioma|Localized Malignant Mesothelioma|Recurrent Malignant Mesothelioma

Estimated Enrollment: 34

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment

Study ID Numbers: NCI-2009-00656|CDR0000539269|N0623|U10CA025224

Study First Received: April 11, 2007

Last Updated: January 28, 2015

Estimated Primary Completion Date: April 2009


Primary Outcome Measures:

Proportion of Evaluable Participants Who Are Progression-free at 6 Months Based on the Response Evaluation Criteria for Solid Tumors (RECIST)|Overall Survival|Progression-free Survival Assessed by RECIST|Determine the Clinical Toxicities of This Drug in This Participant Population.|Overall Best Response of Target Lesions to Pazopanib in Patients With MPM Based on the RECIST.|Overall Response Rate

Sponsors and Collaborators:

National Cancer Institute (NCI)

Website Link:

Leave a Reply

Call Now